As tumors driven by KIT or PDGFRA oncogenic mutations, patients with GIST clearly benefit from the development of molecularly targeted treatments.1 For early-stage/localized GIST amenable to resection, several clinical prognostic factors have been identified and prospectively validated to guide clinical management in terms of surveillance and help decision in guiding adjuvant treatment.2-7 The current clinical factors include age, tumor size, mitotic count, location, and perforation. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.